The National Institute for Health Research Hyperacute Stroke Research Centres and the ENCHANTED trial: the impact of enhanced research infrastructure on trial metrics and patient outcomes by Robinson, TG et al.
RESEARCH Open Access
The National Institute for Health Research
Hyperacute Stroke Research Centres and
the ENCHANTED trial: the impact of
enhanced research infrastructure on trial
metrics and patient outcomes
Thompson G. Robinson1,2,11* , Xia Wang3, Alice C. Durham1, Gary A. Ford4, Joy Liao5, Sine Littlewood6,
Christine Roffe7, Philip White8, John Chalmers3, Craig S. Anderson3,9,10 and on behalf of the ENCHANTED
Investigators
Abstract
Background: The English National Institute for Health Research Clinical Research Network first established
Hyperacute Stroke Research Centres (HSRCs) in 2010 to support multicentre hyperacute (< 9 h) and complex
stroke research. We assessed the impact of this investment on research performance and patient outcomes in
a post-hoc analysis of country-specific data from a large multicentre clinical trial.
Methods: Comparisons of baseline, outcome and trial metric data were made for participants recruited to the
alteplase-dose arm of the international Enhanced Control of Hypertension and Thrombolysis Stroke study
(ENCHANTED) at National Institute for Health Research Clinical Research Network HSRCs and non-HSRCs
between June 2012 and October 2015.
Results: Among 774 ENCHANTED United Kingdom participants (41% female; mean age 72 years), 502 (64.9%) were
recruited from nine HSRCs and 272 (35.1%) from 24 non-HSRCs. HSRCs had higher monthly recruitment rates (median 1.5,
interquartile interval 1.4–2.2 vs. 0.7, 0.5–1.3; p= 0.01) and shorter randomisation-to-treatment times (2.6 vs. 3.1min; p= 0.01)
compared to non-HSRCs. HSRC participants were younger and had milder stroke severity, but clinically important between-
group differences in 90-day death or disability outcomes remained after adjustment for minimisation criteria and important
baseline variables at randomisation, whether defined by ordinal modified Rankin scale score shift (adjusted OR
0.82, 95% CI 0.62–1.08; p = 0.15), scores 2 to 6 (adjusted OR 0.71, 95% CI 0.50–1.01; p = 0.05), or scores 3 to 6
(adjusted OR 0.82, 95% CI 0.57–1.17; p = 0.27). There was no significant difference in symptomatic intracerebral
haemorrhage, nor heterogeneity in the comparative treatment effects between low- and standard-dose
alteplase by HSRCs or non-HSRCs.
Conclusions: Infrastructure investment in HSRCs was associated with improved research performance metrics,
particularly recruitment and time to treatment with clinically important, though not statistically significant,
improvements in patient outcomes.
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Background
Intravenous (iv) alteplase (recombinant tissue plasmino-
gen activator) is the approved medical reperfusion treat-
ment for patients with acute ischaemic stroke and the
earlier the treatment is given, the greater the benefit [1].
However, concerns over risks of intracranial haemorrhage
have led to lower doses of alteplase being used in many
Asian countries [2] after a lower dose (0.6mg/kg) was ap-
proved in Japan. The Enhanced Control of Hypertension
and Thrombolysis Stroke Study (ENCHANTED) assessed
a low dose (0.6mg/kg body weight) compared to the
standard dose (0.9mg/kg) of iv alteplase in acute ischae-
mic stroke patients fulfilling standard criteria for thromb-
olysis (‘clot-busting’ therapy) in improving treatment
efficacy through reduced 90-day death and disability, and
safety through reduced symptomatic intracerebral haem-
orrhage (bleeding associated with neurological deterior-
ation or death) [3]. The primary outcome of the study was
to demonstrate non-inferiority of low- compared to
standard-dose alteplase on 90-day death and disability, de-
fined by scores 2 to 6 on the modified Rankin scale
(mRS). The mRS is a global seven-level assessment of dis-
ability, where scores of 0 to 1 indicate a favourable out-
come with/without symptoms but no disability; 2 to 5
indicate increasing levels of disability and dependency, re-
quiring no (2), weekly (3), daily (4), and 24-h (5) physical
help; and 6 indicates death. Whilst low-dose alteplase was
not non-inferior to the standard dose, it was clearly
non-inferior on a secondary efficacy outcome of shift (‘im-
provement’) in measures of daily function according to
the full range of scores on the mRS scores, and reduced
the risk of symptomatic intracerebral haemorrhage [3].
The United Kingdom had the second highest patient
recruitment (n = 774, 23.3%) to the ENCHANTED alte-
plase dose-arm after China, supported by the National
Institute for Health Research (NIHR) Clinical Research
Network infrastructure for clinical research through the
National Health Service (NHS). In particular, NIHR has
made significant investment in eight (expanding to 10
during the conduct of ENCHANTED) Hyperacute
Stroke Research Centres (HSRCs), established in 2010
with an initial investment of £3.66 million over 3 years.
These high patient volume centres (> 1000 stroke admis-
sions per annum) provide multi-disciplinary expertise in
hyperacute stroke clinical management (including en-
gagement of pre-hospital, emergency department, inter-
ventional neuroradiology, neuroradiology, neuro-critical
care, and neurosurgical staff ), 24/7 availability of ad-
vanced neuroimaging, 7-day per week extended hours
(07:00 to 22:00, minimum) resident research staffing,
and a track record of performing against specialty per-
formance objectives (in particular recruitment to the hy-
peracute (< 9 h of stroke onset) and complex trial
portfolio (a trial requiring complex diagnostics, or sur-
gery/complex intervention, or phase 1 or 2 commercial
study)). In addition, the HSRC selection process includes
a review of recent scores on the Sentinel Stroke National
Audit Programme, particularly related to hyperacute
process metrics, including door-to-scan time, rates of
admission to Hyperacute Stroke Units within 4 h and
thrombolysis rates, where scores at the highest level (A
or B) should be consistently achieved. HSRCs are subject
to annual review by an independent panel to maintain
their accreditation. The return on such investment in in-
frastructure might extend beyond improved research
performance; therefore, whilst we primarily evaluated
the impact of HSRCs on trial metrics, we also assessed
the effect on patient outcomes in NIHR Clinical Re-
search Network sites participating in ENCHANTED in
England.
Methods
Design
The ENCHANTED trial was an international, multi-centre,
prospective, randomised, open-label, blinded-endpoint trial
with a 2 × 2 partial-factorial design to assess the effective-
ness of low- versus standard-dose alteplase (completed
arm) and more intensive versus guideline-recommended
control of blood pressure (ongoing arm), the details of
which are outlined in detail elsewhere [3, 4]. In brief, pa-
tients admitted to hospital with a clinical diagnosis of acute
ischaemic stroke confirmed on brain imaging and fulfilling
local criteria for thrombolysis treatment administered
within 4.5 h of symptom onset, were randomly assigned to
the respective dose arm between 18 June 2012 and 14 Oc-
tober 2015. Randomised patients received low-dose (0.6
mg/kg; 15% as bolus, 85% as infusion over 1 h; maximum
dose 60mg) or standard-dose (0.9mg/kg; 10% as bolus,
90% as infusion over 1 h; maximum dose 90mg) iv alte-
plase. Otherwise, all patients received active care and best
practice management according to local guidelines. The
study protocol was approved by the appropriate ethics
committee at each participating centre, and written
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informed consent was obtained from the patient or an ap-
propriate surrogate.
Procedures
Key demographic and clinical characteristics were re-
corded at the time of enrolment. Stroke severity was
measured using the National Institutes of Health Stroke
Scale at baseline, at 24 h, and on day 7 (or earlier, upon
discharge from hospital). Uncompressed digital images
of all baseline and follow-up brain scans (CT, MRI and
angiogram) were collected, with details of transfer, inter-
pretation and intracranial haemorrhage definitions pro-
vided (Additional file 1).
As previously stated, the primary clinical outcome was
the combined endpoint of death or disability at 90 days,
defined by scores of 2 to 6 on the mRS. Other efficacy
outcomes included an ordinal mRS shift and the com-
bined endpoint of death or major disability (mRS scores
of 3 to 6) at 90 days. The secondary (safety) outcome
was symptomatic intracerebral haemorrhage, defined ac-
cording to several criteria from other studies (Additional
file 1). Additional new analyses in this manuscript focus
on trial performance metrics, including total recruit-
ment, monthly recruitment rate, and times to random-
isation and treatment.
Statistical analysis
The association of HSRC recruitment on global func-
tional outcome (analysis of the full range of day 90 mRS
scores) was estimated using ordinal logistic regression
after the assumption of proportionality of the odds was
confirmed from a likelihood ratio test. Adjustment was
made for the ENCHANTED pre-specified minimisation
variables and several baseline covariates at randomisa-
tion, and additionally for aspects of management over
the first 7 days after hospital admission. In patients from
HSRCs and non-HSRCs, the heterogeneity of the alte-
plase treatment effect was tested by adding an inter-
action term to the statistical models. Data are reported
with odds ratios (ORs) and 95% confidence intervals
(CIs). A two-sided p value of less than 0.05 was consid-
ered statistically significant. SAS version 9.3 (SAS Insti-
tute, Cary, NC) was used for all analyses.
Role of the funding source
The sponsors had no role in the study design, data col-
lection, data analysis, data interpretation or writing of
the report. All authors had full access to the study data.
The corresponding author had final responsibility for
the decision to submit the paper for publication.
Results
These analyses included 774 patients (41% female; mean
age 72 years) randomised to the ENCHANTED trial in
the United Kingdom (England 768, non-England 6), in-
cluding 9 of the 10 established HSRCs (one site did not
participate in ENCHANTED). Although HSRCs com-
prised only 27% (9/33) of recruiting sites, they contributed
nearly two-thirds (502, 64.9%) of participants and had a
significantly higher median monthly recruitment rate than
non-HSRCs (1.5 (interquartile interval 1.4–2.2) vs. 0.7
(0.5–1.3)). With respect to performance on other trial
metrics, Table 1 shows that HSRC patients had signifi-
cantly shorter randomisation-to-treatment times, as well
as differences in other aspects of management, including
angiography and endovascular therapy. Table 2 shows that
participants recruited from HSRCs were significantly
younger, and had milder severity of stroke, as assessed by
National Institutes of Health Stroke Scale or Glasgow
coma score. HSRC patients were also significantly less
likely to develop fever, receive antiplatelet therapy in the
first 24 h after thrombolysis, or have rehabilitation in the
first 7 days, but were more likely to receive subcutaneous
heparin (Additional file 2: Table S1).
Compared to non-HSRC patients, HSRC-treated pa-
tients were significantly less likely to be dead or disabled
at 90 days, whether defined by ordinal shift (unadjusted
OR 0.68, 95% CI 0.52–0.89; p = 0.005), scores 2 to 6
(unadjusted OR 0.63, 95% CI 0.46–0.86; p < 0.0001), or
scores 3 to 6 (unadjusted OR 0.69, 95% CI 0.50–0.82;
Table 1 Selected trial metrics and management of patients by type of stroke research centre
All United Kingdom
(n = 774)
HSRC
(n = 502)
Non-HSRC
(n = 272)
p value
Number of recruiting centres (n) 33 9 24
Monthly recruitment rate (median, IQR) 1.0 (0.6–1.5) 1.5 (1.4–2.2) 0.7 (0.5–1.3) 0.01
Time from stroke onset to treatment, mins (median, IQR) 139 (110–175) 135.5 (110–178) 140.0 (111–174) 0.65
Time from randomisation to treatment, mins (median, IQR) 2.8 (0.2–5.4) 2.6 (−0.6 to 5.3) 3.1 (1.1–5.7) 0.01
Alteplase given (n/N, %) 765/774 (98.8) 498/502 (99.2) 267/272 (98.2) 0.20
Cerebral angiogram (n/N, %) 22/774 (2.8) 20/502 (4.0) 2/272 (0.7) 0.009
Occluded vessel (n/N, %) 18/22 (81.8) 17/20 (85.0) 1/2 (50.0) 0.22
Endovascular therapy (n/N, %) 16/22 (72.7) 15/20 (75.0) 1/2 (50.0) 0.45
HSRC hyperacute stroke research centre, IQR interquartile range
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p = 0.017) on the mRS. There remained clinically im-
portant, though not statistically significant differences in
mortality or disability outcomes at 90 days after adjust-
ment for the minimisation criteria and baseline prognos-
tic variables, whether defined by ordinal shift (adjusted
OR 0.82, 95% CI 0.62–1.08; p = 0.15), scores 2 to 6 (ad-
justed OR 0.71, 95% CI 0.50–1.01; p = 0.05), or scores 3
to 6 (adjusted OR 0.82, 95% CI 0.57–1.17; p = 0.27).
There were no significant differences after further ad-
justment for imbalances in early management (Table 3).
Moreover, no significant differences were seen in
symptomatic intracerebral haemorrhage between HSRC
and non-HSRC patient groups across a broad range of
definitions (Additional file 2: Table S2), nor were there
any significant differences in the treatment effect
(Additional file 2: Tables S3 and S4) or safety (Additional
file 2: Table S5) between low- and standard-dose alte-
plase between HSRC and non-HSRC treated patients.
Discussion
In these country-specific secondary analyses of the
ENCHANTED trial of low- versus standard-dose alteplase
in thrombolysis-eligible acute ischaemic stroke patients,
we have shown significantly higher recruitment rates and
improved trial performance metrics in relation to local re-
search infrastructure investment. HSRCs were established
with additional funding to support hyperacute complex
stroke trials, and while only 9 of the 33 United Kingdom
recruiting centres (England 31, non-England 2) in
ENCHANTED were HSRC designated, they recruited
Table 2 Baseline characteristics of patients by type of stroke research centre
All United Kingdom
(n = 774)
HSRC (n = 502) Non-HSRC (n = 272) p value
Time from stroke onset to randomisation, hours (median, IQR) 2.3 (1.8–2.9) 2.2 (1.8–2.9) 2.3 (1.8–2.8) 0.82
Age, years (mean, SD) 72 (14) 71 (14) 75 (13) 0.0002
Female (n/N, %) 318/774 (41.1) 203/502 (40.4) 115/272 (42.3) 0.62
Non-Asian ethnicity (n/N, %) 757/774 (97.8) 490/502 (97.6) 267/272 (98.2) 0.62
Systolic BP, mmHg (mean, SD) 151 (20) 151 (19) 152 (20) 0.52
Heart rate, bpm (mean, SD) 80 (18) 82 (18) 77 (17) 0.0003
NIHSS score (median, IQR) 7 (5–13) 7 (5–11) 8 (5–14) 0.01
GCS score (median, IQR) 15 (14–15) 15 (14–15) 15 (14–15) 0.01
History of hypertension (n/N, %) 472/774 (61.0) 299/502 (59.6) 173/272 (63.6) 0.27
History of coronary artery disease (n/N, %) 112/774 (14.5) 73/502 (14.5) 39/272 (14.3) 0.94
AF confirmed on ECG (n/N, %) 188/772 (24.4) 117/500 (23.4) 71/272 (26.1) 0.40
Hypercholesterolaemia (n/N, %) 260/774 (33.6) 161/502 (32.1) 99/272 (36.4) 0.22
Current smoker (n/N, %) 124/770 (16.1) 92/501 (18.4) 32/269 (11.9) 0.02
Pre-stroke symptoms on the mRS (n/N, %) 240/773 (31.0) 149/501 (29.7) 91/272 (33.5) 0.29
Antihypertensive therapy (n/N, %) 429/774 (55.4) 264/502 (52.6) 165/272 (60.7) 0.03
Warfarin anticoagulation (n/N, %) 23/773 (3.0) 18/501 (3.6) 5/272 (1.8) 0.17
Aspirin/other antiplatelet (n/N, %) 273/773 (35.3) 178/501 (35.5) 95/272 (34.9) 0.87
Statin/other lipid lowering (n/N, %) 103/773 (13.3) 66/501 (13.2) 37/272 (13.6) 0.87
Brain imaging features
CT scan used (n/N, %) 769/774 (99.4) 502/502 (100) 267/272 (98.2) 0.002
MRI scan used (n/N, %) 8/774 (1.0) 4/502 (0.8) 4/272 (1.5) 0.38
Visible early ischaemic changes (n/N, %) 230/774 (29.7) 156/502 (31.1) 74/272 (15.1) 0.26
Visible cerebral infarction (n/N, %) 144/774 (18.6) 103/502 (20.5) 1/272 (0.4) 0.06
Final diagnosis
Non-stroke (n/N, %) 50/768 (6.5) 33/498 (6.6) 17/270 (6.3) 0.86
Large artery occlusion (n/N, %) 170/713 (23.8) 129/461 (28.0) 41/252 (16.3) 0.003
Small vessel disease (n/N, %) 139/713 (19.5) 91/461 (19.7) 48/252 (19.0)
Cardioembolism (n/N, %) 181/713 (25.4) 106/461 (23.0) 75/252 (29.8)
Other or uncertain aetiology (n/N, %) 223/713 (31.3) 135/461 (29.3) 88/252 (34.9)
HSRC Hyperacute Stroke Research Centre, BP blood pressure, NIHSS National Institutes of Health Stroke Scale, GCS Glasgow coma scale, AF atrial fibrillation, mRS
modified Rankin scale
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nearly two-thirds of all the patients in the United
Kingdom, and with faster recruitment and shorter
randomisation-to-treatment times. Furthermore, whilst
90% of English HSRCs participated in ENCHANTED, the
participation rate was far lower amongst the English
non-HSRC sites, at 21% (24/117). HSRC-treated patients
had significantly better clinical outcomes in the
unadjusted analyses, which remained clinically, though
not quite statistically, significant after adjustment for
minimisation criteria and differences in baseline
characteristics. No differences were seen compared to
non-HSRC-treated patients after adjustment for early
management, which may reflect better care processes in
HSRCs.
The importance of research is explicitly stated in The
Handbook to the NHS Constitution in the United
Kingdom [5]. Indeed, the NIHR Clinical Research Net-
work was specifically established with the aim of im-
proving the health and well-being of the nation, through
research focused on the needs of patients and the public.
In the field of stroke, additional funding in the HSRC
network was directed to deliver hyperacute (randomisa-
tion < 9 h of symptom onset) and/or complex studies
(using advanced neuroimaging or other diagnostics,
interventional neuroradiology or neurosurgery). An as-
sessment of any positive impact of this research infra-
structure investment on research performance measures
and health outcomes would be important to demon-
strate to NHS commissioners and providers the value of
research infrastructure funding. To our knowledge, this
is the first such evaluation on the return on this HSRC
investment.
Table 3 Clinical outcomes at 90 days in patients by type of stroke research centre
n (%) Unadjusted OR (95% CI) p value Adjusted ORa (95% CI) p value Adjusted ORb (95% CI) p trend
Death or disability (mRS 2 to 6)
Non-HSRC 165/256 (64.5) 1.0 0.004 1.0 0.05 1.0 0.87
HSRC 249/467 (53.3) 0.63 (0.46–0.86) 0.71 (0.50–1.01) 0.97 (0.64–1.46)
Death or disability (mRS 3 to 6)
Non-HSRC 121/256 (47.3) 1.0 0.017 1.0 0.27 1.0 0.82
HSRC 178/467 (38.1) 0.69 (0.50–0.82) 0.82 (0.57–1.17) 1.05 (0.68–1.62)
Death
Non-HSRC 34/272 (12.5) 1.0 0.24 1.0 0.60 1.0 0.58
HSRC 49/502 (9.8) 0.76 (0.48–1.21) 0.87 (0.51–1.47) 1.21 (0.61–2.39)
mRS categories
Non-HSRC 1.0 0.005 1.0 0.15 1.0 0.77
0 37 (14.5)
1 54 (21.1)
2 44 (17.2)
3 45 (17.6)
4 23 (9.0)
5 19 (7.4)
6 34 (13.3)
HSRC 0.68 (0.52–0.89) 0.82 (0.62–1.08) 1.05 (0.77–1.43)
0 100 (21.4)
1 118 (25.3)
2 71 (15.2)
3 61 (13.1)
4 42 (9.0)
5 26 (5.6)
6 34 (13.3)
CI confidence interval, HSRC hyperacute stroke research centre, mRS modified Rankin score, OR odds ratio, aOR adjusted odds ratio
aModel 1: adjusted analysis for minimisation variables including National Institutes of Health Stroke Scale score and time from stroke onset to randomisation, and
baseline variables: age, sex, ethnicity, systolic blood pressure, heart rate, hypercholesterolaemia, current smoker, premorbid mRS, premorbid use of
antihypertensive therapy, aspirin or other antiplatelet agent, and randomised treatment (low dose versus standard dose)
bModel 2: as Model 1, plus systolic blood pressure at 24 h, fever occurrence, nasogastric feeding given, subcutaneous heparin used, patient mobilised by therapist,
any stroke unit admission, any neurosurgery performed, and any rehabilitation given
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Analyses of practice-based research networks in the
United States have shown improved clinical outcomes in
participating practices [6], whilst previous NIHR data
analyses have shown that Trusts with the lowest mortal-
ity for adult non-elective admissions had higher levels of
research patient recruitment and funding than those
with expected or higher mortality rates [7]. The survival
benefits for research participants and other patients sep-
arately persist after adjustment for staffing and other
hospital structural factors such as medical and staffing
ratios per bed, critical care versus general bed ratios, and
affiliations with a university [7]. Our study provides fur-
ther support for positive impact of research investment
on research participation, trial performance metrics and
patient recruitment.
In addition, though we were unable to clearly demon-
strate a statistically significant association between re-
search investment and improved patient outcomes in
adjusted (as opposed to unadjusted) analyses, this is most
likely related to the sample size and thus the limited statis-
tical power to confirm modest but still clinically important
differences. Indeed, even after adjustment for minimisa-
tion criteria and baseline differences, we were able to
demonstrate a borderline statistical, but clinically signifi-
cant, 29% reduction in 90-day death and disability, defined
by a mRS of 2 to 6. Jonker and Fisher [8] were also unable
to show that the degree of NIHR portfolio clinical re-
search activity was significantly related to risk rating for
overall performance by the Care Quality Commission.
Nonetheless, another study of high-risk conditions, in-
cluding stroke, has shown a significant correlation be-
tween academic output, as measured by citations per
hospital admission, and overall mortality [9]. Furthermore,
a study of colorectal cancer outcome by the NIHR Cancer
Research Network reported a significant reduction in
post-operative mortality and improved 5-year survival in
research-active centres [10]. Indeed, there are other exam-
ples of improved patient outcome and adherence to guide-
lines in hospitals participating in related clinical trials
compared to other hospitals, for example, in relation to
the management of non-ST-segment elevation acute cor-
onary syndromes [11].
Several possible mechanisms have been proposed for
why clinical research may improve health outcomes, in-
cluding enhanced infrastructure and organisation, multi-
disciplinary and institutional collaboration, education and
training, specialisation, and care processes, particularly in
the uptake and adherence to guideline-recommended care
[12, 13]. In particular, HSRCs provide enhanced infra-
structure, including 7-day per week extended hours (07:00
to 22:00, minimum) resident research staffing and im-
proved collaboration between key specialties in hyperacute
stroke management. These mechanisms are supported by
two recent systematic reviews, which concluded that a
strong research culture has patient, staff and organisa-
tional benefits [14], and that institution and clinician en-
gagement in clinical trials has greater adherence to
guidelines and better outcomes [15]. Whilst we were un-
able to explore these themes retrospectively, a qualitative
study has reinforced their relevance in an NIHR context
at the NIHR Oxford Biomedical Research Centre [16].
Another potential explanation for the research and clinical
benefits of HSRCs on patient care processes and outcomes
may relate to a ‘volume effect’ [17]. One of the criteria in-
cluded in HSRC designation is the number of annual
stroke admissions, with the average annual admission rate
in HSRCs being higher compared to non-HSRCs (1713
(range 820–2920) vs. 971 (288–1556)) [18].
We acknowledge that our study is limited by being
based on data derived from a single country where the
open-label trial design may have introduced various
biases despite our efforts at concealment of treatment al-
location, assessment of adverse events and blinded
evaluation of clinical outcomes using established criteria.
Moreover, as the ENCHANTED trial included patients
with generally milder stroke severity with a slightly lon-
ger treatment delay from onset than in previous trials or
registries [19], there may be further concerns over the
generalisability of these data, and imprecision in the esti-
mates of the effects may have arisen from variability in
the assessment of the mRS [20]. In addition, the propor-
tion of female patients is lower than might be expected
given the age demographic of stroke, and highlights re-
gional differences in sex distribution between registry
and trial populations, with male predominance being
previously reported in stroke thrombolysis trials [21]. Fi-
nally, it is difficult to determine if the improved research
performance of HSRCs was related to the research infra-
structure investment associated with their designation as
an HSRC, or whether these were already high perform-
ing research centres or clinical Hyperacute Stroke Units.
Only one centre changed status from a non-HSRC to a
HSRC during the trial, with average monthly recruit-
ment rates of 1.3 and 2.4 over 29 months before and 4.5
months after change in HSRC status, respectively. How-
ever, five HSRCs participated in the Third International
Stroke Trial, between May 2000 and July 2011 [22],
which is a similar trial comparing iv thrombolysis with
control treatment up to 6 h following acute ischaemic
stroke onset. Average monthly recruitment rates in-
creased by approximately 50% from 0.8 and 1.1 between
April 2007 and March 2010 (pre-HSRC status) and April
2010 to July 2011 (HSRC status), respectively.
Conclusions
We have demonstrated a positive impact of research in-
frastructure investment, with significant improvements
in overall recruitment and other trial performance
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metrics in HSRCs, including monthly recruitment rates
and time to randomisation and treatment. This also led
to broader clinically important benefits in patient out-
comes, even after adjustment for differences in mini-
misation criteria and baseline characteristics, though
these did not reach statistical significance. This should
provide confidence to commissioners and providers of
the importance of research investment and participation,
as highlighted in the NHS Constitution.
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